Full-year highlights

Very strong 2016, well ahead of strategic goals
Sales up 3% to €7,920m, with 4% organic growth
Adjusted EBITDA1 up 17% to €1,262m
ROCE up 280 bps to 10.4% driven by 38% increase in Adjusted EBIT1
Cash from operating activities up 27% to €1,018m
Net profit of €629m compared to €92m in 2015
Proposed dividend increase from €1.65 to €1.75 per ordinary share
Full year key figures and indicators (continuing operations)

in € million FY 2016 FY 2015 % change
volume price/
mix FX
other
Sales 7,920 7,722 3% 4% 0% -1% 0%
Nutrition 5,169 4,963 4% 3% 2% -1% 0%
Materials 2,513 2,528 -1% 4% -5% -1% 1%
Adjusted EBITDA1 1,262 1,075 17%
Nutrition 931 822 13%
Materials 435 384 13%
EBITDA 1,174 956
ROCE (%) 10.4% 7.6%
1) Main non-IFRS terms are explained on page 23 'Notes to the condensed financial statements'. A reconciliation is provided on pages 15 and 17.

CEO statement

Feike Sijbesma, CEO/Chairman of the DSM Managing Board, commented: “With today’s results, we are clearly delivering on the goals we set out at the end of 2015. We are pleased to report a very good year, in which we achieved strong EBITDA and ROCE growth, well ahead of the mid-term targets set out in Strategy 2018: Driving Profitable Growth.

Nutrition achieved a year of strong organic growth, in both Animal and Human Nutrition & Health. The Materials transformation is apparent in strong volume and margin growth, driven by our focus on specialties. In addition, we made good progress on our extensive improvement programs. Besides stepping up our financial performance, we were also able to drive our innovation and sustainability agenda in 2016, as well as taking further steps in anchoring the organizational agility and culture that we aim at.

While macro-economic conditions are uncertain, we are confident that in 2017 we will again deliver on our strategic objectives, despite a higher comparative base year. We will continue to execute our growth initiatives, and we are firmly on track with our ambitious, group-wide cost and productivity improvement programs. In addition, we will maintain our disciplined approach to capital allocation and working capital.”

Outlook 2017
DSM aims to deliver high single-digit percentage Adjusted EBITDA growth and high double-digit basis point ROCE growth in line with the targets set out in its Strategy 2018.

Q4 highlights

Sales up 5% to €2,015m, with 2% organic growth
Adjusted EBITDA1 up 21% to €315m
Nutrition: 2% organic sales growth; Adjusted EBITDA up 16%
Materials: 7% volume growth; Adjusted EBITDA up 17%
Cash from operating activities up 19% to €374m

zie en lees meer op
http://www.dsm.com/corporate/media/informationcenter-news/2017/02/03-17-dsm-q4-and-annual-results-2016.html

tijd 09.01
De AEX 496.22 +1,60 +0,32% DSM EUR 60,94 -2ct vol. 22.106